Charles Schwab Investment Management Inc. trimmed its stake in Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 12.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 460,016 shares of the company's stock after selling 63,478 shares during the period. Charles Schwab Investment Management Inc. owned about 1.00% of Avanos Medical worth $7,323,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in AVNS. US Bancorp DE lifted its holdings in Avanos Medical by 18.0% in the fourth quarter. US Bancorp DE now owns 14,093 shares of the company's stock valued at $224,000 after buying an additional 2,147 shares during the period. Illinois Municipal Retirement Fund boosted its position in shares of Avanos Medical by 3.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 25,236 shares of the company's stock valued at $402,000 after purchasing an additional 748 shares in the last quarter. Paradice Investment Management LLC boosted its position in shares of Avanos Medical by 2.5% during the 4th quarter. Paradice Investment Management LLC now owns 1,293,198 shares of the company's stock valued at $20,588,000 after purchasing an additional 30,949 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in Avanos Medical during the fourth quarter worth approximately $989,000. Finally, Principal Financial Group Inc. increased its holdings in Avanos Medical by 3.5% in the fourth quarter. Principal Financial Group Inc. now owns 237,794 shares of the company's stock worth $3,786,000 after purchasing an additional 7,932 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of Avanos Medical stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now owns 82,047 shares of the company's stock, valued at approximately $1,251,216.75. The trade was a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.90% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised shares of Avanos Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, March 19th.
Check Out Our Latest Stock Analysis on Avanos Medical
Avanos Medical Stock Up 1.1 %
AVNS stock traded up $0.16 during mid-day trading on Thursday, reaching $14.32. 353,569 shares of the company traded hands, compared to its average volume of 553,549. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The firm's 50 day moving average price is $15.73 and its 200 day moving average price is $18.48. The stock has a market cap of $658.62 million, a price-to-earnings ratio of 42.11 and a beta of 1.17. Avanos Medical, Inc. has a fifty-two week low of $14.10 and a fifty-two week high of $25.36.
Avanos Medical (NYSE:AVNS - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The company had revenue of $179.60 million during the quarter, compared to the consensus estimate of $177.23 million. As a group, equities research analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.
About Avanos Medical
(
Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Featured Articles
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
